RecruitingNot ApplicableNCT05520151

Influence of Preoperative Immunomodulation by Oral Impact on Postoperative Complications Following Cystectomies & Nephrectomies

Influence of Preoperative Immunomodulation by Oral Impact® on Postoperative Complications Following Cystectomies and Nephrectomies


Sponsor

Centre Hospitalier Intercommunal Robert Ballanger

Enrollment

214 participants

Start Date

Nov 30, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynecological and cardiac surgery. Studies in major Urological surgery are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • years of age and older
  • Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies.
  • Having expressed their free and informed consent.
  • Affiliated to a social security scheme

Exclusion Criteria7

  • Immune deficiency.
  • HIV infection.
  • Curative surgery for chronic urinary tract infection.
  • Urgent surgery.
  • Inability to take oral impact 7 days before surgery.
  • Unstable psychiatric state.
  • Infection with COVID 19 during postoperative stay.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTORAL IMPACT treatment

the group of patients will be received a 7-days course of ORAL IMPACT

OTHERcontrol

no intervention


Locations(2)

CHI Robert Ballanger

Aulnay-sous-Bois, France

CHI André Grégoire

Montreuil, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05520151


Related Trials